Tuesday, November 4, 2008

FDA Approves Additional Indication for Norditropin for Small for Gestational Age (SGA) in Children

Children born with a condition that can prevent them from growing to a normal height now have a new treatment option available with the approval of Norditropin(R) (somatropin [rDNA origin] injection) for the treatment of short stature in children born Small for Gestational Age (SGA) with no catch-up growth by age 2-4 years.

The details can be read here.

No comments: